Bayer

The company is headquartered in Leverkusen, Germany, and has been led by chief executive Bill Anderson since June 2023; in July 2025, Bayer said its supervisory board extended his contract through March 31, 2029. 

In pharmaceuticals, Bayer’s growth narrative has increasingly centered on newer brands, particularly Nubeqa in prostate cancer and Kerendia in chronic kidney disease associated with type 2 diabetes, as older products face competitive and patent pressures. Company reporting through 2025 continued to highlight momentum in these franchises alongside lifecycle management for other key medicines. 

Operationally, Bayer has been running a multi-year organizational transformation intended to reduce hierarchy and speed decision-making. In January 2024, the company announced a new operating model, “Dynamic Shared Ownership,” described as a shift toward fewer management layers and greater accountability closer to execution. The restructuring has been accompanied by headcount reduction, which Bayer has publicly framed as part of broader cost and efficiency targets. 

The group’s strategic context remains shaped by contrasting dynamics across its divisions. Pharmaceuticals is positioned as the key contributor to medium-term margin and cash generation, while crop science has faced cyclical pricing pressure and continued exposure to U.S. litigation linked to glyphosate. In parallel, Bayer has communicated that resolving remaining glyphosate cases and strengthening the pharma pipeline are central management priorities within its current structure.